Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP569477.RAZtlSH_24CiFNErLNZ5-_KRhe_ddHEzqdYHWdU9gws_M130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP569477.RAZtlSH_24CiFNErLNZ5-_KRhe_ddHEzqdYHWdU9gws_M130_assertion type Assertion NP569477.RAZtlSH_24CiFNErLNZ5-_KRhe_ddHEzqdYHWdU9gws_M130_head.
- NP569477.RAZtlSH_24CiFNErLNZ5-_KRhe_ddHEzqdYHWdU9gws_M130_assertion description "[Here, we demonstrated that silencing of AGPS in chemotherapy resistance glioma U87MG/DDP and hepatic carcinoma HepG2/ADM cell lines resulted in reduced cell proliferation, increased drug sensitivity, cell cycle arrest and cell apoptosis through reducing the intracellular concentration of lysophosphatidic acid (LPA), lysophosphatidic acid-ether (LPAe) and prostaglandin E2 (PGE2), resulting in reduction of LPA receptor and EP receptors mediated PI3K/AKT signaling pathways and the expression of several multi-drug resistance genes, like MDR1, MRP1 and ABCG2.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP569477.RAZtlSH_24CiFNErLNZ5-_KRhe_ddHEzqdYHWdU9gws_M130_provenance.
- NP569477.RAZtlSH_24CiFNErLNZ5-_KRhe_ddHEzqdYHWdU9gws_M130_assertion evidence source_evidence_literature NP569477.RAZtlSH_24CiFNErLNZ5-_KRhe_ddHEzqdYHWdU9gws_M130_provenance.
- NP569477.RAZtlSH_24CiFNErLNZ5-_KRhe_ddHEzqdYHWdU9gws_M130_assertion SIO_000772 24815474 NP569477.RAZtlSH_24CiFNErLNZ5-_KRhe_ddHEzqdYHWdU9gws_M130_provenance.
- NP569477.RAZtlSH_24CiFNErLNZ5-_KRhe_ddHEzqdYHWdU9gws_M130_assertion wasDerivedFrom befree-20150227 NP569477.RAZtlSH_24CiFNErLNZ5-_KRhe_ddHEzqdYHWdU9gws_M130_provenance.
- NP569477.RAZtlSH_24CiFNErLNZ5-_KRhe_ddHEzqdYHWdU9gws_M130_assertion wasGeneratedBy ECO_0000203 NP569477.RAZtlSH_24CiFNErLNZ5-_KRhe_ddHEzqdYHWdU9gws_M130_provenance.